Shares of jumped more than 5 per cent in early trade on Monday after the company announced a landmark acquisition of US-based Organon & Co in a deal valued at $11.75 billion, marking the largest overseas buy by the Indian drugmaker and the domestic pharmaceutical industry.
The stock was trading at ₹1,698.90 on the NSE at 9:38 am, after surging to an intraday high of ₹1,709, compared with the previous close of ₹1,620.40. The sharp rally reflects strong investor sentiment following the announcement of the all-cash transaction.
Under the agreement, Sun Pharma will acquire all outstanding shares of Organon at $14 per share. The deal significantly expands the company’s global footprint and strengthens its position in key therapeutic segments, particularly in the US market.
Market participants are viewing the acquisition as a strategic move that could drive long-term growth, although attention will remain on execution, integration, and its impact on future earnings.